129
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Impact of Highly Active Antiretroviral Therapy in the Treatment of HIV–Infected Patients with Systemic Non-Hodgkin‘s Lymphoma

, , , , , , & show all
Pages 192-196 | Published online: 08 Jul 2009

  • Mueller N. Overview of the epidemiology of malignancy in immune de ciency. J Acquir Immune De? c Syndr 1999; 21 (Suppl 1): 5-10.
  • Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunode? ciencies. J Pediatrics 1995; 126: 1-10.
  • Beral V, Newton R. Overview of the epidemiology of im-munode ciency associated cancers. J Natl Cancer Inst Monographs 1998; 23: 1-5.
  • Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunode ciency virus type 1. J Natl Cancer Inst 1994; 86: 1711-6.
  • Jones Jl, Hanson DL, Dworkin MS, Ward JW, Jaffe HW and the Adult:Adolescent spectrum of HIV disease. Effect of antiretroviral therapy on recent trends in selected cancers among HIV‘infected persons. J Acquir Immune De c Syndr 1999; 21 (Suppl 1): S11-S7.
  • Cote TR, Biggar RJ, Rosenberg PS, et al. Non‘Hodgkin‘s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS:Cancer Study Group. Int J Cancer 1997; 73: 645-50.
  • Ratner L, Redden D, Hamzeh F, et al. Chemotherapy for HIV associated non-Hodgkin‘s lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third National AIDS Malignancy Conference, Bethesda, MD, 1999 (Abstract 92).
  • Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunode ciency virus infection. N Engl J Med 1992; 326: 1037-42.
  • Palella FJ, Delaney KM, Moornan AC, et al. Declining morbidity and mortality among patients with advanced human immunode? ciency virus infection. N Engl J Med 1998; 338:853-60.
  • Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunode? ciency virus infection and CD4 counts of 2000 per cubic milimeter or less. N Engl J Med 1997;337:725-33.
  • Centers for Disease Control and Prevention Update. Trends in AIDS incidence, deaths, and prevalence--United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46: 861-867.
  • Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classi? cation of hematological malignancies. Report of the clinical advisory committee meeting, Airlie House, Virginia. Mod Pathol 1997; 13: 193-207.
  • Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin‘s disease staging classi? cation. Cancer Res 1971; 31: 1860-1.
  • Kimby E, Brandt L, Nygren P, Glimelius B. A systematic overviewofchemotherapyeffectsinaggressivenon-Hodgkin‘s lymphoma. Acta Oncol 2001; 40: 198-212.
  • Hanna GJ, Hirsch MS., Antiretroviral therapy of human imunode? ciency virus infection. In: Mandell GL, Bennett JE Dolin R, eds. Priciples and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000: 1479-99.
  • Cheson BD, Horning SJ, Coif? er B, et al. Report of an international workshop to standardize response criteria for Non-Hodgkin‘s lymphomas. J Clin Oncol 1999; 17: 1244-53.
  • Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census (letter). N Engl J Med 1997; 336: 1531-2.
  • Centers for Disease Control and Prevention. Report of the NIH panel to de? ne principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 5: 1-82.
  • Kaplan L. Therapeutic approaches to HIV-associated non-Hodgkin‘s lymphoma., The American Society of Hematology Education Program Book 1999; 522-528.
  • Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in humanimmunode? ciencyvirus-relatednon-Hodgkin‘s lymphoma: a single-institute study of 96 patients. J Clin Oncol 1996; 14: 2217-22.
  • Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of HIV-associated non-Hodgkin‘s lymphoma. Analysis of AIDS Malignancy Clinical Group (ACTG) protocol 142: low-dose vs. standard-dose m-BACOD GM-CSF. J Clin Oncol 1998; 16: 3601-11.
  • Tirelli U, Spina M, Gabarre J, et al. Treatment of HIV-related non-Hodgkin‘s lymphoma adapted to prognostic factors. Third National AIDS Malignacy Conference, Bethesda, MD, 1999 (Abstract 91).
  • Bower M, Sten S, Fife K, Nelson M, Gazzard BG. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. Eur J Cancer 2000; 36: 363-7.
  • Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 1991; 266: 84-90.
  • Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunode? ciency virus related lymphoma treated with intensive combination chemotherapy. Am J Med 1993; 95: 188 -96.
  • Tirelli U, Errante D, Spina M, et al. Second-line chemotherapy inhumanimmunode? ciency virus-associated non-Hodgkin‘s lymphoma. Cancer 1996; 77: 2127-31.
  • for the French Italian Cooperative Study Group, Tirelli U, Errante D, Oksenhendler E, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin‘s lymphoma. Ann Oncol 1992; 3: 843-7.
  • Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effectsofrecombinanthumangranulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunode? ciency virus-associated non-Hodgkin‘s lymphoma: results of a randomized trial. J Clin Oncol 1991; 9: 929 -40.
  • Kaplan LD, Straus DJ, Testa MA, et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin‘s lymphoma associated with human immuno-def? ciency virus infection. N Engl J Med 1997; 336: 1642-8.
  • Navarro JT, Ribera JM, Oriol A, et al. Effect of highly active antiretroviral therapy (HAART) on response to therapy and survivalinpatientswithAIDS-relatednon-Hodgkin‘s lymphoma treated with CHOP. Blood 1999; 94: 525a.
  • Vaccher E, Spina M, Talamani R, et al., Concomitant CHOP chemotherapy and HAART in patients with HIV-related non-Hodgkin‘s lymphoma. Proc Am Soc Clin Oncol 1998; 17: 47a (Abstract 184).
  • Bower M, Matthews G, Powles T, Mandalia S, Nelson M, Gazzard BL. Changes in AIDS-related lymphoma (ARL) in the era of highly active antiretroviral therapy (HAART). J Clin Oncol 2000; 19: 17a.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.